Sublingual immunotherapy in pediatric patients: Beyond clinical efficacy

Purpose of review: Sublingual immunotherapy (SLIT) is widely used in several European countries. Many clinical trials and a meta-analysis presently support its efficacy, but limits and indications in pediatric age still need to be clarified. We review here the most recent literature on SLIT, with pa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Baena Cagnani, Carlos E., Passalacqua, Giovanni, Baena Cagnani, Rodrigo C., Croce, Víctor Hugo, Canonica, Giorgio Walter
Formato: Artículo
Lenguaje:Español
Publicado: 2005
Materias:
R Medicina (General)
Acceso en línea:http://pa.bibdigital.ucc.edu.ar/3994/1/A_BaenaCagnani_Passalacqua_BaenaCagnani_Croce_Canonica.pdf
Aporte de:
Producción Académica Universidad Católica de Córdoba (UCCor) de Universidad Católica de Córdoba
id I38-R144-3994
record_format dspace
spelling I38-R144-39942025-04-07T20:25:31Z http://pa.bibdigital.ucc.edu.ar/3994/ Sublingual immunotherapy in pediatric patients: Beyond clinical efficacy Baena Cagnani, Carlos E. Passalacqua, Giovanni Baena Cagnani, Rodrigo C. Croce, Víctor Hugo Canonica, Giorgio Walter R Medicina (General) Purpose of review: Sublingual immunotherapy (SLIT) is widely used in several European countries. Many clinical trials and a meta-analysis presently support its efficacy, but limits and indications in pediatric age still need to be clarified. We review here the most recent literature on SLIT, with particular attention paid to the safety of children and to the additional clinical effects. Recent findings: In addition to clinical trials, post-marketing surveillance studies have confirmed the optimal safety profile of SLIT in adults and children, including those below the age of 5 years. The most recent studies have shown that SLIT identically to the subcutaneous route, has the potential to affect the immunological response to allergens. This is testified to by the facts that SLIT can prevent the onset of new sensitizations and maintain its beneficial effect for years after discontinuation. Moreover, it has been shown that SLIT can prevent the onset of asthma in children with rhinitis. Summary: Due to its excellent safety, SLIT would be an optimal candidate for use in pediatric age groups, where the natural history of allergy can be to some extent modified. Nonetheless, formal and rigorous studies are needed to define its exact indication and dosage. 2005-04-30 info:eu-repo/semantics/article info:eu-repo/semantics/closedAccess application/pdf spa http://pa.bibdigital.ucc.edu.ar/3994/1/A_BaenaCagnani_Passalacqua_BaenaCagnani_Croce_Canonica.pdf Baena Cagnani, Carlos E., Passalacqua, Giovanni, Baena Cagnani, Rodrigo C., Croce, Víctor Hugo and Canonica, Giorgio Walter ORCID: https://orcid.org/0000-0001-8467-2557 <https://orcid.org/0000-0001-8467-2557> (2005) Sublingual immunotherapy in pediatric patients: Beyond clinical efficacy. Current Opinion in Allergy and Clinical Immunology, 5 (2). pp. 173-177. ISSN 1528-4050 info:eu-repo/semantics/altIdentifier/doi/10.1097/01.all.0000162311.87178.9e
institution Universidad Católica de Córdoba
institution_str I-38
repository_str R-144
collection Producción Académica Universidad Católica de Córdoba (UCCor)
language Español
orig_language_str_mv spa
topic R Medicina (General)
spellingShingle R Medicina (General)
Baena Cagnani, Carlos E.
Passalacqua, Giovanni
Baena Cagnani, Rodrigo C.
Croce, Víctor Hugo
Canonica, Giorgio Walter
Sublingual immunotherapy in pediatric patients: Beyond clinical efficacy
topic_facet R Medicina (General)
description Purpose of review: Sublingual immunotherapy (SLIT) is widely used in several European countries. Many clinical trials and a meta-analysis presently support its efficacy, but limits and indications in pediatric age still need to be clarified. We review here the most recent literature on SLIT, with particular attention paid to the safety of children and to the additional clinical effects. Recent findings: In addition to clinical trials, post-marketing surveillance studies have confirmed the optimal safety profile of SLIT in adults and children, including those below the age of 5 years. The most recent studies have shown that SLIT identically to the subcutaneous route, has the potential to affect the immunological response to allergens. This is testified to by the facts that SLIT can prevent the onset of new sensitizations and maintain its beneficial effect for years after discontinuation. Moreover, it has been shown that SLIT can prevent the onset of asthma in children with rhinitis. Summary: Due to its excellent safety, SLIT would be an optimal candidate for use in pediatric age groups, where the natural history of allergy can be to some extent modified. Nonetheless, formal and rigorous studies are needed to define its exact indication and dosage.
format Artículo
author Baena Cagnani, Carlos E.
Passalacqua, Giovanni
Baena Cagnani, Rodrigo C.
Croce, Víctor Hugo
Canonica, Giorgio Walter
author_facet Baena Cagnani, Carlos E.
Passalacqua, Giovanni
Baena Cagnani, Rodrigo C.
Croce, Víctor Hugo
Canonica, Giorgio Walter
author_sort Baena Cagnani, Carlos E.
title Sublingual immunotherapy in pediatric patients: Beyond clinical efficacy
title_short Sublingual immunotherapy in pediatric patients: Beyond clinical efficacy
title_full Sublingual immunotherapy in pediatric patients: Beyond clinical efficacy
title_fullStr Sublingual immunotherapy in pediatric patients: Beyond clinical efficacy
title_full_unstemmed Sublingual immunotherapy in pediatric patients: Beyond clinical efficacy
title_sort sublingual immunotherapy in pediatric patients: beyond clinical efficacy
publishDate 2005
url http://pa.bibdigital.ucc.edu.ar/3994/1/A_BaenaCagnani_Passalacqua_BaenaCagnani_Croce_Canonica.pdf
work_keys_str_mv AT baenacagnanicarlose sublingualimmunotherapyinpediatricpatientsbeyondclinicalefficacy
AT passalacquagiovanni sublingualimmunotherapyinpediatricpatientsbeyondclinicalefficacy
AT baenacagnanirodrigoc sublingualimmunotherapyinpediatricpatientsbeyondclinicalefficacy
AT crocevictorhugo sublingualimmunotherapyinpediatricpatientsbeyondclinicalefficacy
AT canonicagiorgiowalter sublingualimmunotherapyinpediatricpatientsbeyondclinicalefficacy
_version_ 1832592422851313664

Ejemplares similares